RxDoctor Payments Data

Megan Hebert

Family · Lake Charles, LANPI 1912401621

Payments from drug & device makers

$6,755in general payments, 2019–2025

Across 183 payments — averaging $36.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$3K
  • AstraZeneca$537
  • Amgen$444
  • ANI Pharmaceuticals, Inc.$428
  • Otsuka America Pharmaceutical, Inc.$421
  • Vifor Pharma, Inc.$404
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$1,50022%
  • Travel & lodging$5799%
  • Food & beverage$4,49166%
  • Education$1853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,755 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide29$47,827
AuryxiaFerric Citrate31$41,585
Sevelamer Carbonate165$19,403
Lanthanum Carbonate22$15,385
VeltassaPatiromer Calcium Sorbitex20$13,719
ProsolParenteral Amino Acid 20% No.138$7,055
Calcium Acetate103$6,431
Nifedipine ErNifedipine62$1,245
Hydralazine Hcl69$737
Furosemide70$513
Labetalol Hcl14$468
Minoxidil15$365
Lactulose11$345
Losartan Potassium46$317
Carvedilol42$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$2,966$47,82729 claims
Akebia Therapeutics IncAuryxia$95$41,58531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.

Other family in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →